At the news
? NEUTRALIMPACT 4/10 8-K filed May 7, 2026 at 08:10 ET
Atara reported that after a Type A meeting with the FDA, the agency agreed that a single-arm study with an appropriate historical control could support resubmission of the tabelecleucel (tab-cel) BLA. Partner Pierre Fabre plans to submit an updated dataset from the ALLELE study with additional patients and longer follow-up. The company expects a further regulatory update in Q3 2026.
- FDA agreed a single-arm study with historical control could support tab-cel BLA resubmission.
- Pierre Fabre intends to submit updated ALLELE study data with more patients and longer follow-up.
- Next regulatory update expected in Q3 2026.
- Tab-cel BLA received a Complete Response Letter on January 9, 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access